

Corporate Overview

April 2018


Forward-Looking Statements

This presentation contains, and any accompanying oral presentation would no doubt contain, forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding Biocept, Inc. and our business. Forward-looking statements include all statements that are not historical facts and generally can be identified by terms such as anticipates, believes, could, estimates, expects, intends, may, plans, potential, predicts, projects, should, will, would, or the negative of those terms and similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For details about these risks, please see our SEC filings.

All forward-looking statements contained in this presentation speak only as of the date hereof, and except as required by law, we assume no obligation to update these forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Corporate Profile



Investment Highlights

Liquid Biopsy Market Estimated at \$10+ Billion

- Potential to improve cancer patient outcomes
- Advantages of a simple blood test vs. tissue biopsy (convenience, repeatability, feasibility benefits, reduced cost and fewer complications)

Test Menu Focused Only on Actionable Information

- Unique CTC and ctDNA testing
- Enables detection and monitoring of clinically-validated biomarkers listed in NCCN Guidelines

Industry-Leading Test Performance

- Multiple clinical studies, publications, and presentations support Biocept's proprietary Target Selector™ platform

Opportunities for Value-Creating Strategic Partnerships

- Potential for U.S. and Global Transactions
- Commercial and Technology Partnerships

Strong Revenue Growth and Health Plan Reimbursement

- 4-year Revenue CAGR of 300%*
- Indicative of platform validation and market potential
- Cost-effective liquid biopsy testing

Evolution Toward Distributed Business Model

- Actively growing Pathology Partnership (ie TC-PC) business
- Target Selector Kits for both CTC and ctDNA platforms

*Through 3Q 2017 and includes conversion to accrual revenue recognition in 1Q 2017

Anticipated Near Term Milestones

- ✓ Continue to grow commercial liquid biopsy volume and revenue
- ✓ Enter into strategic sales and technology partnerships – Global and U.S.
- ✓ Sign additional Empower TC agreements with pathologists and major hospitals
- ✓ Validate Oncomine™ NGS Panel; Become Thermo Fisher Liquid Biopsy Center of Excellence
- ✓ Launch blood collection tubes under VWR marketing and distribution agreement
- ✓ Sign new third-party health plan agreements and expand relationship with BCBS
- ✓ Publish clinical case studies
- ✓ Launch additional oncology biomarker assays

Patients Diagnosed with Cancer in the US

Estimated New Cases

			Males	Females		
Prostate	161,360	19%			Breast	252,710 30%
Lung & bronchus	116,990	14%			Lung & bronchus	105,510 12%
Colon & rectum	71,420	9%			Colon & rectum	64,010 8%
Urinary bladder	60,490	7%			Uterine corpus	61,380 7%
Melanoma of the skin	52,170	6%			Thyroid	42,470 5%
Kidney & renal pelvis	40,610	5%			Melanoma of the skin	34,940 4%
Non-Hodgkin lymphoma	40,080	5%			Non-Hodgkin lymphoma	32,160 4%
Leukemia	36,290	4%			Leukemia	25,840 3%
Oral cavity & pharynx	35,720	4%			Pancreas	25,700 3%
Liver & intrahepatic bile duct	29,200	3%			Kidney & renal pelvis	23,380 3%
All Sites	836,150	100%			All Sites	852,630 100%

- » Over 1.68 million new cases in 2017
- » Breast, lung, and CRC account for >36% of all new cases of cancer

Estimated Deaths

			Males	Females		
Lung & bronchus	84,590	27%			Lung & bronchus	71,280 25%
Colon & rectum	27,150	9%			Breast	40,610 14%
Prostate	26,730	8%			Colon & rectum	23,110 8%
Pancreas	22,300	7%			Pancreas	20,790 7%
Liver & intrahepatic bile duct	19,610	6%			Ovary	14,080 5%
Leukemia	14,300	4%			Uterine corpus	10,920 4%
Esophagus	12,720	4%			Leukemia	10,200 4%
Urinary bladder	12,240	4%			Liver & intrahepatic bile duct	9,310 3%
Non-Hodgkin lymphoma	11,450	4%			Non-Hodgkin lymphoma	8,690 3%
Brain & other nervous system	9,620	3%			Brain & other nervous system	7,080 3%
All Sites	318,420	100%			All Sites	282,500 100%


- » More than 610,000 people will die of cancer in 2017
- » Breast, lung, and CRC account for >41% of all cancer related deaths

» Source: American Cancer Society 2017 – SEER Statistics

Liquid Biopsy Global Market Opportunity



Liquid Biopsy market segments




"We sized the [global] market opportunity for liquid biopsy as \$22B by 2020..."

**J.P. Morgan Industry Report - May 27, 2015*

Molecular Profiling of Cancer Biomarkers

The Standard of Care in Personalized Treatment



Identification of Molecular Biomarkers Required to Qualify Patients for Targeted Therapy

Biocept
Completing the Answer™

OncoCEE-BR™ Circulating Tumor Cell (CTC) Test

3910 Henry Road, Suite 100, San Diego, CA 92121
Client Service: 858-552-1729 FAX: 617-555-5555 www.biocept.com

PATIENT INFORMATION		CLIENT INFORMATION	
Patient Name:	Patient, south 1234	Ordering Physician:	Sam Smith, MD
Patient ID#:	C100524	Order Location:	Sam's Father Cancer Institute
Address:	450 Brookline Avenue Boston, MA 02215	Address:	450 Brookline Avenue Boston, MA 02215
Date of Birth:	12/13/1918	Account Number:	55555121
Sex:	F	Phone:	617-555-5555
		Fax:	617-555-5555

SPECIMEN INFORMATION	
Accession #:	DFW 0010
Client Account #:	1219-KX-KX
Specimen Type:	Peripheral
Wet Weight (mg):	15
Collected Date:	1/7/2014 8:00 PM
Received Date/Time:	1/9/2014 9:45 AM
Reported Date/Time:	1/9/2014 12:31 PM
Test(s) Ordered:	HER2 (OncoCEE-BR™)

RESULTS	
Diagnosis:	History of Breast Cancer
CTCs:	Present
HER2:	Amplified (Positive)

SUPPORTING DATA

Enumeration of Circulating Tumor Cells by OncoCEE™ 179
HER2 Analysis of CTCs by OncoCEE™ 179: Amplified (Positive)

Parameter	Value
Number of CTCs	189
Number of CTCs, HER2 amplified CTCs	1
Number of CTCs, HER2 amplified CTCs	1

CTC image:


HER2 image:

Supporting Data: Enumeration of Circulating Tumor Cells by OncoCEE™ 179. HER2 Analysis of CTCs by OncoCEE™ 179: Amplified (Positive). Circulating tumor cells (CTCs) were detected in peripheral blood submitted in test kit OncoCEE™ 179. PCR analysis for HER2 showed evidence of HER2 amplification. Clinical investigation before that presence of circulating tumor cells (CTCs) in blood is an indicator of metastatic disease. Metastasis is a complex multi-step process that includes epithelial-mesenchymal transition (EMT), in which tumor cells are characterized by loss of cell adhesion, expression of E-cadherin, acquisition of mesenchymal markers, increased cell motility, and invasiveness. (HER2) is recognized as an important predictive and prognostic factor in breast cancer. (2) HER2 status is predictive of a potential response to HER2 targeted agents such as (trastuzumab) (3).


Laboratory Director: Sam Smith, MD, FACMG, FRCPC (RCPC)
CLIA ID Number: 0400000

Accession #: DFW 0010
Page 1 of 2

Personalized Treatment \Rightarrow Improved Outcomes




Source: SEER Cancer Statistics Review 1975-2013
cancer.gov





*NCI Cancer Statistics https://seer.cancer.gov/csr/1975_2014/browse_csr.php?sectionSEL=2&pageSEL=sect_02_table.08.html

Matching Cancer Patients to Personalized Therapy Remains Challenging



Legacy Cancer Diagnostic Tools Do Not Tell The Complete Story

	Advantages	Disadvantages	Cost
 <p>Traditional Surgical Biopsy</p>	<ul style="list-style-type: none"> ▪ Required for diagnosis ▪ Considered standard of care ▪ Source of cancer (histology) ▪ Results for all known oncogenic alterations ▪ Analysis of whole cells 	<ul style="list-style-type: none"> ▪ Invasive – not appropriate for monitoring ▪ Risk of adverse events ▪ Expensive ▪ Often inadequate for complete molecular profiling ▪ Only 57% of tissue biopsies have sufficient tissue for analysis ▪ Can take as much as 30 days for results ▪ Heterogeneity of tumor can lead to false negatives ▪ Does not account for evolving cancer over time – snapshot view 	<p>\$15,000 to \$45,000</p>
 <p>NGS Based Liquid Biopsy Panels</p>	<ul style="list-style-type: none"> ▪ Real time ▪ Non-invasive – appropriate for profiling ▪ Faster availability of results 	<ul style="list-style-type: none"> ▪ Cannot deliver information on all biomarkers ▪ Varying sensitivity and specificity by biomarker ▪ Expensive ▪ Non-clinically actionable information ▪ One size fits all approach – not individualized ▪ Based solely on DNA fragments – ctDNA ▪ Target market – medical oncology only 	<p>\$6,800</p>

Biocept Solves the Problem by Combining the Best of Both Worlds

Target Selector Biopsy – Completing the Answer™




The Biocept Advantage

- ✓ Combined results from whole cells (CTCs) and ctDNA from a single blood sample
 - ✓ Enables results for all types of oncogenic alterations including SNVs, Indels, Fusions, CNVs, and Protein Expression
- ✓ Turnaround in 7 days or less enabling targeted therapy to move into frontline
- ✓ Individually validated all alterations – delivers high concordance with tissue
- ✓ Marketed as single tests or profiles enables personalized results for each patient
- ✓ Value – pay for individual and/or actionable alterations only
- ✓ Reimbursement advantages
- ✓ Addresses challenges of tumor heterogeneity
- ✓ Real time results versus static snapshots
- ✓ Non-invasive - appropriate for both profiling and monitoring
- ✓ Target market – medical oncology and pathology
- ✓ Broad, international patent coverage

✓ Cost = \$1,200

Patient Case Study – Biocept’s Testing Provides “The Gift of Time”

Biocept’s Target Selector Enables Personalized Treatment for Non-Small Cell Lung Cancer (NSCLC) Patient After Tissue Biopsy Proves Inadequate



Highly Relevant Test Menu:

Industry Leading Assays Trusted by Clinicians, Patients, and Payers

15 Actionable Biomarkers Found in the Guidelines

Cancer	Target Selector CTC	Target Selector ctDNA
Breast	HER2*, ER*, FGFR1, AR, PDL1, PR*	ESR1 mutations
Gastric	HER2*, FGFR1	
Lung	ALK*, ROS1*, MET*, FGFR1, PDL1*, RET	EGFR*, KRAS*, BRAF* mutations, ALK mutations
Colon	EGFR amplification	KRAS*, BRAF*, NRAS* mutations
Prostate	AR, ARv7	
Melanoma		BRAF*, NRAS* mutations

* In NCCN guidelines

- Biomarkers currently available for clinical use
- Biomarkers under development

Industry-Leading Assay Performance


Controlled Validation Concordance (standard criteria) – 99.3%

CTC Biomarkers + ctDNA Analytical Validation	CTC Biomarkers + ctDNA Analytical Combined
Data Size (N)	4641
Accuracy	4610/4641 (99.3%)
Sensitivity	99.2%
Specificity	99.6%

Concordance to Tissue (real-world experience) - 87%

CTC Biomarkers + ctDNA Clinical Validation	CTC Biomarkers + ctDNA Clinical Combined
Data Size (N)	407
Accuracy	354/407 (87%)
Sensitivity	74%
Specificity	94.6%

Premier Commercial Platform



Differentiated Product Offerings

Company	CTCs / Whole Cells	ctDNA / DNA Fragments	Proprietary Collection Tube	Pathology Partnership Strategy
Genomic Health (GHDX)		✓		
Epic Sciences (private)	✓			
Foundation Medicine (FMI)		✓		
Guardant Health (private)		✓		
Biocept (BIOC)	✓	✓	✓	✓

Biocept Advantage

- Leading company commercializing both CTCs and ctDNA from a single blood sample
- Demonstrated high concordance with tissue
- Assays for most appropriate tumor target from blood for each biomarker
- Blood more likely to contain intact cells and is less fragmented than other fluids such as urine
- Broad, international patent coverage
- Cost and reimbursement advantages

Biocept IP Portfolio

Family 1

MicroChannel for CTC Capture

- Patent 1 – Recovery of rare cells using microchannel
- Patent 2 – Device for Cell Separation

1) Issued in US with 11 international counterparts

- China – Korea – China - France – Germany – Great Britain
Italy – Spain – Hong Kong – Japan – pending Aus. – Can.

2) Issued in US

2025

Family 2

CTC Capture With Antibody Cocktail

- Patent 1 – Devices & Methods of Cell Capture Analysis
- Patent 2 – Method and Reagents for Signal Amplification

1) Issued in US with 8 international counterparts

- Aus. – France – Germany – Great Britain – Spain – Italy – Hong Kong - Japan – pending in Can - China

2) Issued in US, Japan, and China - 4 international cases pending

- Canada – Europe - Hong Kong –Korea

2030

Family 3

Collection Tube

Patent 1 – Use of DU for Anti-Clumping of Biological Sample

1) Issued in US

2031

Family 4

Switch Blockers for ctDNA Analysis

Patent 1 – Methods for Detecting Nucleic Acid Sequence Variants

1) Issued in US, Australia, and China with 4 international counterparts

Europe – Japan – Hong Kong – Korea – Brazil


2033

Extensive IP portfolio expected to allow Biocept to monetize IP through out-licensing and moving to distributed model based on developing diagnostic kits

Market Development

Current Salesforce Coverage

Sales Mgt. Sales Exec NCCN Center



Customer Focus

- Target select cancer center regions
- Focus on community oncologists (80% of cancer care)
- Partner with integrated delivery networks and local pathologists

Commercial team

- Experienced leadership
- Regionally based team with significant oncology sales experience
- Managed care expertise


14 direct sales representatives in the field

Commercial Adoption



- Executing on strategy to contract with major cancer treatment institutions, GPOs, and distributors
- Increasing patient access
- Accelerating adoption of liquid biopsy
- Leveraging sales and marketing resources by increasing awareness of Biocept's liquid biopsy platform within large health systems
- Roll out new tests and service offerings including molecular pathology partnering model (ie "TC-PC")

“AND” Campaign Debut at ASCO 2017



Target Selector™
Liquid Biopsy

Increasing Targeted Therapies via Liquid Biopsy

When treating cancer patients, it's no longer an either/or world.

At Biocept, we're
all about the **AND...**

It's time to consider molecular information from both
tissue **AND** blood.

Biocept is the industry's first to offer cancer biomarker
testing using both ctDNA **AND** CTCs.

Focused on approved NCCN biomarkers, Biocept's tests
include targeted therapy **AND** immunotherapy markers.

Visit Booth #25160 to learn about Biocept's Liquid Biopsy Technology.
www.biocept.com

EmpowerTC™ Launch at CAP 2017



Empower TC™
Tech-Only Liquid Biopsy

Empowering Local Pathologists
With World-Class Diagnostics

The first in the industry to offer cancer biomarker testing using both ctDNA **AND** CTCs.

Biocept offers specialized tests for approved NCCN biomarkers, including targeted therapy **AND** immunotherapy markers.

ctDNA

- BRAF
- EGFR
- KRAS
- NRAS

CTC

- ALK
- AR
- ER
- FGFR1
- HER2
- MET
- PD-L1
- PR
- RET
- ROS1
- CTC Count



Our World-Class Lab. Your Expertise.

Partner with Biocept for **Tech-Only Services** that combine our leading **CTC Testing Technology** with **Your Local Knowledge**.

ALK Gene Rearrangement by FISH: DETECTED (1 CTC/16 mL)

Case Study: Biocept's Liquid Biopsy Enables Personalized Treatment for Non-Small Cell Lung Cancer (NSCLC) Patient After Tissue Biopsy Proves Inadequate.

Customer Service 888-332-7729 • FAX 877-300-1761

Biocept, Inc.

5810 Nancy Ridge Drive, San Diego, CA 92121

www.biocept.com



© 2017 Biocept, Inc. All rights reserved. Target Selector is a trademark of Biocept, Inc. NCCN Guidelines is registered trademark of National Comprehensive Cancer Network, Inc.

MKTG-0036-02

Collaboration with Thermo Fisher Scientific



- Validate Thermo Fisher Oncomine™ NGS Panel in Biocept's CLIA-certified laboratory
- Once validated, Biocept to be designated as Thermo Fisher Liquid Biopsy "Center of Excellence" for oncology-focused liquid biopsy initiatives with the companies jointly pursuing various commercial opportunities
- Initially target the pharmaceutical industry to provide diagnostic testing services for drug development, clinical trial support, and companion diagnostics (CDx)
- Collaboration also intends to evaluate the feasibility of developing best-in-class products based on the integration of Biocept's Target Selector™ technology with Thermo Fisher's Ion Torrent™ NGS platform and Oncomine™ liquid biopsy-based NGS panels.


Health Plan Access Continues to Expand with Third Party Contracts




- Managed Care agreements in place covering >200 million lives
- Dedicated managed care leadership with years of experience from GE, LabCorp and Quest
- Payors have positive coverage for biomarkers listed in guidelines
- Aligns with goals of healthcare reform
- Improved outcomes while reducing costs
- Utilize established CPT codes

Deploying Capital To Fuel Accelerated Growth

Annual Revenue




Annual Patient Samples



Note: FY 2017 includes \$1.2M related to revenues recognized upon the receipt of payment.


Biocept – Execution of Value Creation Strategy

- Investment in technology development of over \$100M resulting in full commercialization
- Liquid Biopsy moving from early adopter orders to mainstream clinician orders for profiling.
- First liquid biopsy (plasma based EGFR testing) now in NCCN guidelines – will increase routine adoption (“AND” campaign)
- Early adopters now using for monitoring for response or progression indicating that the broader group will follow over coming year
- Biocept is a market leader in the space
- 14 sales representatives in the field – driving deeper market penetration
- Only liquid biopsy company to market to oncologist and pathologist by providing value to both, with a goal of standardization at the institutional level
- Paid today by payors as coverage policies exist for Biocept menu, therefore generating revenue – per accession revenue of approx \$1000 - \$1200.
- At beginning of 2016, approx 5% of the cash needs provided by operations, today approx 17% 5 year



Appendix

Patented Target Selector™ Platform Enables both CTC and ctDNA Analysis




Benefits:

- CTCs obtained through our platform can be used to molecularly characterize tumor cells and evaluate changes in protein expression with the same techniques done in tissue.
- The same specimen can be microscopically analyzed for DNA and protein targets.
- All CTC tests are enumerated and can be used in monitoring applications.

Patented Target Selector™ Platform Enables both CTC and ctDNA Analysis

Benefits:



- Performing PCR upfront and then sequencing delivers added confidence to final result.
- Switch-Blocker technology enriches oncogene mutations and suppresses wild type DNA resulting in ultra-high sensitivity and specificity.
- All ctDNA tests are quantitative and can be used to monitor mutation load.
- NGS technology allows multiplexing capabilities and future panel development.



Biocept Publications, Posters, and Abstracts

37 Scientific/Clinical Presentations

- 7 Peer-Reviewed Journal Publications
- 23 Poster Presentations at Leading Scientific/Clinical Meetings
- 1 Technology Description
- 6 Abstracts: Scientific/Clinical Meetings



Partners in Establishing Clinical Utility

- Collaborations with major cancer centers
- Participating in medical meetings and symposia
- Engaging KOL Advisors
- Building relationships with patient advocacy groups
- Expanding strategic partnerships with pharma and biotech for personalized diagnostics

INSIGHT
GENETICS

BCM[®]
Baylor College of Medicine

Pro Genetics.
Advanced Tumor Profiling

UC Irvine Health
School of Medicine

SARAH CANNON
Fighting Cancer Together™

DANA-FARBER
CANCER INSTITUTE

COLUMBIA UNIVERSITY
MEDICAL CENTER
Discover. Educate. Care. Lead.

MedStar Georgetown
University Hospital

UC San Diego
MOORES CANCER CENTER

Masonic Cancer Center
UNIVERSITY OF MINNESOTA
Comprehensive Cancer Center designated by the National Cancer Institute

SOUTHWESTERN
MEDICAL CENTER

ROSETTA GENOMICS™
expanding personalized medicine

ALCMI
‘al-kə-mē
ADDARIO
LUNG CANCER
MEDICAL INSTITUTE

AstraZeneca

Catalyst
pharmaceuticals

THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center
Making Cancer History™

University of
Colorado Hospital
UNIVERSITY OF COLORADO HEALTH

Yale University
School of Medicine

Biocept
Completing the Answer™

Landmark Clinical Trial for Liquid Biopsy

The Addario Lung Cancer Medical Institute (ALCMI) is an international research consortium driving clinical research via a world-class team of investigators from 25 member institutions in the U.S. UK, and Europe. It is supported by a dedicated centralized research infrastructure including standardized biorepositories and data systems.



- 400 Lung Cancer Patients
- 25 Treatment Sites (U.S. and International)
- 1 Year Study Duration Evaluating Clinical Utility of Biocept Liquid Biopsy Testing
- Up to 2,400 Liquid Biopsy Data Points
- Key Endpoints:
 - Demonstrate Concordance vs. Tissue
 - Evaluate Response To Drug Therapy
 - Identify Resistance Mechanisms
 - Predict Treatment Failure Early

Our Team has a Deep & Successful History of Commercializing Innovation

Michael Nall
President & CEO

- 25+ years in healthcare sales, marketing and commercial operations
- 16 years in cancer diagnostics and genomics
- Most recently General Manager N. American Sales and Marketing for Clariant—a GE Healthcare Company

Tim Kennedy
CFO & SVP of Operations

- 30+ years of financial experience, 25+ years in the clinical diagnostics industry
- Instrumental in 2.1B restructuring of Millennium Health, a privately-held urine drug lab
- Numerous senior management positions – helped transform PLUS Diagnostics into largest independent U.S pathology lab; merged National Health Labs and Roche Biomedical Labs to form LabCorp

Lyle Arnold, Ph.D.
SVP, R&D & CSO

- Senior R&D leadership at Gen-Probe, Incyte Genomics, Genta
- Founder/ Co-founder Oasis Biosciences, Molecular Biosystems, Aegea Biotechnologies
- Former faculty member, UCSD School of Medicine and member, UCSD Cancer Center
- 47 issued US and more than 140 issued and pending patents worldwide

Veena Singh, MD
SVP & Sr. Medical Director

- Board certified AP/CP and Molecular Pathology, UCSD, Cedars Sinai trained
- Numerous publications, serves on CAP committees
- Most recently Medical Director – bioTheragnostics

Michael Terry
SVP, Commercial Operations

- 25+ years commercial leadership experience in molecular Dx and med-tech companies
- Former GE Healthcare executive, certified in Six Sigma
- Recent experience in liquid biopsy field; EVP commercial operations at both Sequenom and Trovagene

David Moskowitz, RPh
VP Strategy & Corporate Communications

- 16-year Wall Street professional - sell-side equity analyst and research director
- 25+years of healthcare industry experience; #1 biotech stock-picker 2011 (Starmine)
- Strategic consultant to numerous companies in pharma, biotech, and diagnostics sectors



Biocept is Guided by a Board of Visionaries & Scientific Influencers

Board of Directors

David F. Hale

Chairman

Bruce E. Gerhardt, CPA

Director, Member Audit Committee

M. Faye Wilson, CPA, MBA

Lead Independent Director, Chair Audit Committee, Member Compensation Committee, Member Nominating and Governance Committee

Ivor Royston, MD

Director, Chair – Science and Technology Committee, Member Nominating and Governance Committee

Marsha A. Chandler, PhD

Director, Chair - Nominating and Governance Committee, Member Science and Technology Committee

Bruce A. Huebner

Director, Chair – Compensation Committee, Member – Science and Technology Committee, Member – Audit Committee

Michael W. Nall

Director, President & CEO

Clinical Advisory Board

Lee Schwartzberg, MD

Chief, Division of Hematology Oncology; Professor of Medicine, University of Tennessee

David Carbone, MD

Director, James Thoracic Center, James Cancer Hospital and Solove Research Institute, Ohio State University

Jenny Chang, MD

Director, Methodist Hospital Cancer Center, Houston, Texas

Michael Kosty, MD

Scripps Clinic Torrey Pines, San Diego California

Edgardo Santos, MD

Medical Director, Lynn Cancer Institute, Boca Raton, Florida

Melissa Johnson, MD

Medical Oncologist, Nashville, Tennessee

Fred Hirsch, MD, PhD

CEO, Int'l Assoc. of Study of Lung Cancer; Professor of Medicine, University of Colorado

Santosh Kesari, MD, PhD

Chair, Dept. of Translational Neuro-oncology and Neurotherapeutics, John Wayne Cancer Institute, Santa Monica California

Scientific Advisory Board

David Rimm, MD, PhD

Professor of Pathology and Medicine (Oncology) Yale University School of Medicine

Marileila Garcia, PhD

Professor, University of Colorado Division of Medical Oncology

Achievements Since Going Public

Now	At IPO
✓ Revenue to \$4.1M in first 9 months of 2017	\$0 Revenue
✓ In-house billing and collections	Outsourced
✓ 26 Issued Patents	1
✓ 16 Members on Commercial Team	None
✓ Multiple health plan agreements signed including BCBS plans covering over 200M lives	None
✓ 4 Pharma Agreements	None
✓ Nearly 30 ongoing clinical studies & numerous published papers and presentations at medical and scientific conferences	Less than 6
✓ Multitudes of patients helped	Minimal

Biocept